The pharmaceutical industry is approaching one of its most consequential commercial transitions. Between 2026 and 2030, several blockbuster medicines will face patent expirations, generic competition, or biosimilar entry. For major drug makers, the challenge extends beyond losing market exclusivity. They must replace billions in established revenue while developing medicines through AI in drug discovery that can sustain future growth.
The pharmaceutical patent cliff is particularly important for companies that depend heavily on a handful of successful treatments. Merck & Co., Bristol Myers Squibb (BMS), and Pfizer face significant exposure, while AbbVie and Novartis are already demonstrating how portfolio transitions can soften the impact alongside healthcare technology innovation.
However, patent expiration does not automatically mean immediate revenue collapse. Litigation, regulatory exclusivity, settlement agreements, and new formulations can change the commercial timeline. Let’s examine the eight pharmaceutical giants, their most exposed medicines, and the strategies they are using to protect their future.


